Literature DB >> 6587365

Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.

D O Adams, T Hall, Z Steplewski, H Koprowski.   

Abstract

Monoclonal antibodies of the IgG2a isotype specifically inhibit the growth of human tumors in nude mice; tumors in mice given no antibody, an antibody of the IgG2a isotype that does bind to the tumor cells, or an antibody of the IgG2b isotype grow progressively. In the present work it is demonstrated that tumors of mice given the IgG2a antibody are essentially masses of necrosis, while tumors from the control mice are sheets of healthy tumor cells. Tumors of the treated mice, in comparison to controls, contain an increased number of macrophages, and these macrophages are activated for a distinct form of cytolysis dependent on antibodies of the IgG2a isotype. The data suggest that changes in the number and function of intratumoral macrophages are a major component of tumor destruction mediated by IgG2a antibodies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6587365      PMCID: PMC345537          DOI: 10.1073/pnas.81.11.3506

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

Review 1.  The cell biology of macrophage activation.

Authors:  D O Adams; T A Hamilton
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

2.  Mac-1: a macrophage differentiation antigen identified by monoclonal antibody.

Authors:  T Springer; G Galfré; D S Secher; C Milstein
Journal:  Eur J Immunol       Date:  1979-04       Impact factor: 5.532

3.  Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.

Authors:  M Herlyn; Z Steplewski; D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

4.  Immunologic factors influencing the intra-tumor localization of ADCC effector cells.

Authors:  S Haskill; E Parthenais
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Suppression of antibody-sensitized tumor cells by macrophages: insufficient supply or activation of macrophages within large tumors.

Authors:  R J Johnson; R F Siliciano; H S Shin
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

6.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

7.  Sequential activation of murine mononuclear phagocytes for tumor cytolysis: differential expression of markers by macrophages in the several stages of development.

Authors:  W J Johnson; P A Marino; R D Schreiber; D O Adams
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

8.  Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum.

Authors:  T J Matthews; J J Collins; G J Roloson; H J Thiel; D P Bolognesi
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

9.  Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction.

Authors:  A J Langlois; T Matthews; G J Roloson; H J Thiel; J J Collins; D P Bolognesi
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

10.  Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen.

Authors:  C C Badger; I D Bernstein
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  48 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

2.  Inhibition of antibody-dependent cell-mediated cytolysis of tumor cells by Fc receptor of human cytomegalovirus. Brief report.

Authors:  T Murayama; K Shimokawa; T Furukawa
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.

Authors:  M K Song; S W Lee; Y S Suh; K J Lee; Y C Sung
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.

Authors:  H Mellstedt; J E Frödin; P Ragnhammar; G Masucci; J Shetye; B Christensson; P Biberfeld; J Makower; P Pihlstedt; B Cedermark
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

6.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

Review 10.  Effects of tumor growth on host defenses.

Authors:  G J Cianciolo; R Snyderman
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.